Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000512692 | SCV000608958 | uncertain significance | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | MERTK: PM2, PM3, PP3 |
Labcorp Genetics |
RCV000512692 | SCV002172180 | uncertain significance | not provided | 2021-06-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with clinical features of MERTK-related conditions (PMID: 29555955). ClinVar contains an entry for this variant (Variation ID: 444514). This variant is present in population databases (rs747894786, ExAC 0.001%). This sequence change replaces glycine with aspartic acid at codon 787 of the MERTK protein (p.Gly787Asp). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and aspartic acid. |
Institute of Human Genetics, |
RCV004817744 | SCV005069841 | likely pathogenic | Retinal dystrophy | 2019-01-01 | criteria provided, single submitter | clinical testing |